Select a medication above to begin.
Camzyos
mavacamten
Black Box Warnings .
Appropriate Use
avail. only through restricted distribution program (Camzyos REMS) due to heart failure risk from systolic dysfxn; prescribers, pts, and pharmacies must enroll at 1-833-628-7367 or www.CAMZYOSREMS.com
Heart Failure Risk
LVEF decr. may cause heart failure from systolic dysfxn; echocardiogram required before tx initiation and during tx; avoid tx initiation in pts w/ LVEF <55%; interrupt tx if LVEF <50%, heart failure s/sx, or worsening clinical status; contraindicated w/ moderate-strong CYP2C19 inhibitors, strong CYP3A4 inhibitors, moderate-strong CYP2C19 inducers, or moderate-strong CYP3A4 inducers
Adult Dosing .
Dosage forms: CAP: 2.5 mg, 5 mg, 10 mg, 15 mg
Restricted Distribution in US
- [1-833-628-7367 or www.CAMZYOSREMS.com for more info]
obstructive hypertrophic cardiomyopathy, NYHA Class II-III
- [2.5-15 mg PO qd]
- Start: 5 mg PO qd, titrate dose based on Valsalva LVOT gradient and LVEF q4wk x12wk, then q12wk; Max: 15 mg/day; Info: consider delay dose incr. or hold tx if serious illness or arrhythmia; hold tx if LVEF <50% and restart when LVEF 50% or greater; D/C tx if LVEF <50% x2 on 2.5 mg PO qd; see pkg insert for tx initiation, maintenance, and interruption dose adjustment details; do not open cap
renal dosing
- [see below]
- eGFR >30: no adjustment; eGFR <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.